What is the long-term trend for Supernus Pharmaceuticals's other commercial liabilities?

Over 5 years (2020 to 2025), Supernus Pharmaceuticals's other commercial liabilities has grown at a 6.4% compound annual growth rate (CAGR), from $78.93M to $107.8M.

Supernus Pharmaceuticals SUPN Other Commercial Liabilities

Other Commercial Liabilities at other companies

Catalyst PharmaceuticalCPRX

——

Jazz PharmaceuticalsJAZZ

——

Acadia PharmaceuticalsACAD

——

Praxis Precision Medicines, Inc.PRAX

——

Bausch + LombBLCO

——

Other financials

Income statement

See full

Revenue$207.7M+38.6%

Gross profit$184.3M+37.5%

Operating income-$8.3M+18.8%

Net income-$2.3M+80.6%

EPS (diluted)-$0.04+81.0%

Balance sheet

See full

Cash & equivalents$186.3M+60.8%

Total debt$40.9M+26.6%

Total equity$1.1B+4.5%

Total assets$1.5B+11.4%

Cash flow

See full

Operating cash flow$66.5M+117%

CapEx--100%

Free cash flow$66.5M+120%

Valuation

See full

Market cap$2.58B+62.8%

Enterprise value$2.44B+62.3%

P/S3.3×+0.9×

Profitability

See full

Gross margin89.4%+1.0pp

Operating margin-7.8%-18.9pp

Net margin-3.7%-13.0pp

FCF margin27.9%+3.4pp

Returns & leverage

See full

Return on equity-2.8%-9.1pp

Debt / equity0×0.0×

Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's other commercial liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Supernus Pharmaceuticals's other commercial liabilities?: Supernus Pharmaceuticals (SUPN) reported other commercial liabilities of $101.24M in Q1 2026.
How has Supernus Pharmaceuticals's other commercial liabilities changed year-over-year?: Supernus Pharmaceuticals's other commercial liabilities increased by 31.7% year-over-year, from $76.89M to $101.24M.
What is the long-term trend for Supernus Pharmaceuticals's other commercial liabilities?: Over 5 years (2020 to 2025), Supernus Pharmaceuticals's other commercial liabilities has grown at a 6.4% compound annual growth rate (CAGR), from $78.93M to $107.8M.